price month
reflect us tax reform consist
adjust estim post call rais ep
lower effect tax rate
previous suggest albeit rather inform
see note increment disclosur tax reform howev nov
suggest elimin certain deduct tax cut
job act addit new intern provis could lead
higher rate would nevertheless like come lower
pleas reach would like copi latest model
risk includ unfavor drug price trend difficulti integr
 close
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
healthcar servic product compani
distribut brand gener pharmaceut well broad
varieti medic surgic product
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
compani mention price
